VAVirginia Carrizo Abarza

Virginia Carrizo Abarza

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Virginia Carrizo Abarza has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dual Targeted Therapy as a Treatment Strategy for Refractory Psoriatic Arthritis: Real‐World Effectiveness and Safety From a Prospective Cohort

    by André Lucas Ribeiro, Zahra Al‐Zahir, Virginia Carrizo Abarza, Khalad Maliyar, Siddhartha Sood, Ahmed Bagit, Muskaan Sachdeva, Sahil Koppikar, Dafna D. Gladman, Jensen Yeung, et al.

    Objective: To describe patient profiles, treatment patterns, clinical outcomes, and safety of intentional dual biologic or targeted synthetic disease‐modifying antirheumatic drug (b/tsDMARD) therapy in psoriatic arthritis (PsA). A subset of patients with PsA continue to experience persistent inflammation despite b/tsDMARD monotherapy. Dual b/tsDMARD therapy has emerged as a potential strategy in refractory cases, but evidence in PsA remains limited. Methods: We conducted a nested study within the International Psoriasis and Arthritis Research Team prospective cohort. Adults satisfying Classification Criteria for Psoriatic Arthritis who received two concurrent b/tsDMARDs (TNFi, IL‐17i, IL‐23i, JAKi, TYK2i, with or without apremilast) for ≥60 days were included. Baseline features, previous therapies, indications for dual therapy, and disease activity measures (tender joint count in 68 joints, swollen joint count in 66 joints, Disease Activity Index for Psoriatic Arthritis [DAPSA], Psoriasis Area and Severity Index [PASI], body surface area, patient visual analog scale) were collected. Clinical outcomes were reassessed at three‐ to six‐month intervals, with effectiveness assessed only for dual bDMARD + JAK/TYK2i combinations. Safety was evaluated through all‐cause adverse events. Results: Thirty‐nine patients initiated dual therapy: 24 patients received bDMARD + JAK/TYK2i and 15 patients with bDMARD + apremilast. Patients were highly treatment‐experienced (median two conventional synthetic DMARDs and five b/tsDMARDs). Indications included refractory peripheral arthritis, concurrent joint and skin activity, palmoplantar or nail psoriasis, and persistent enthesitis. Among bDMARD + JAK/TYK2i combinations, improvements were observed in joint counts, DAPSA, PASI, and patient‐reported outcomes. Adverse events were infrequent and mild. Conclusions: In this real‐world cohort, dual b/tsDMARD therapy was feasible, well‐tolerated, and associated with clinical improvement in patients with refractory PsA. These findings support its individualized use and highlight the need for controlled studies to define long‐term safety and optimal combination strategies.

  • Open Access

    Impact of depression and anxiety on the components of minimal disease activity (MDA) in patients with psoriatic arthritis

    by Virginia Carrizo Abarza, Pankti Mehta, Fadi Kharouf, Shangyi Gao, Richard J. Cook, Denis Poddubnyy, Dafna D. Gladman, Vinod Chandran

    Background: We have previously demonstrated that the presence of depression/anxiety reduces the probability of achieving sustained Minimal Disease Activity (MDA) in patients with psoriatic arthritis (PsA). Objective: We now aimed to investigate whether the presence of depression/anxiety affects the likelihood of achieving components of MDA in patients with PsA. Design: Observational cohort study using longitudinal data from a prospective PsA cohort. Methods: We included PsA patients satisfying classification criteria, prospectively followed from 2008 to 2024. We defined the presence of depression/anxiety by one of three criteria 1 a score of ≤38 on the SF-36 Mental Component Summary score, 2a score of ≤56 on the SF-36 Mental Health domain, or 3 a rheumatologist’s report of a diagnosis or treatment for depression/anxiety. Generalized Estimating Equations were utilized to evaluate the association between depression/anxiety and being in a state of MDA, as well as each of the seven MDA components. Results: Among 1,130 PsA patients studied, 659 patients (58.3%) met at least one definition of depression/anxiety. The presence of depression/anxiety was associated with a 63% lower likelihood of achieving MDA. Patients with depression/anxiety were significantly less likely to 6 of the 7 MDA criteria, including tender joint count ≤1, swollen joint count ≤1, tender entheseal points ≤1, pain visual analogue scale (VAS) ≤15, global disease activity VAS ≤20, and HAQ score ≤0.5. No association was found between depression/anxiety and achieving PASI≤1. Conclusion: In PsA patients, the presence of depression/anxiety reduces the odds of achieving all criteria of MDA except PASI.

  • Do Patients Diagnosed With Psoriatic Arthritis Before or Concurrently With Psoriasis Have Different Disease Phenotypes and Outcomes?

    by Matthew Anacleto-Dabarno, Fadi Kharouf, Virginia Carrizo Abarza, Pankti Mehta, Shangyi Gao, Daniel Pereira, Richard J. Cook, Denis Poddubnyy, Vinod Chandran, Dafna D. Gladman

    Objective: This study aimed to investigate whether patients who present with psoriatic arthritis (PsA) before or concurrently with psoriasis exhibit different baseline characteristics and disease outcomes compared with patients with classical PsA, in whom psoriasis precedes PsA. We also characterized factors contributing to the onset of psoriasis in these patients. Methods: We included patients with PsA from an observational cohort and classified them into 3 groups: classical PsA (psoriasis diagnosed before PsA), concurrent disease (psoriasis and PsA diagnosed within 1 year), and antecedent PsA (PsA diagnosed > 1 year before psoriasis). We assessed the association between these groups and 2 outcomes: mean disease activity and the course of radiographic damage. We used multivariable linear regression to estimate the adjusted 5-year mean swollen joint count (SJC) and Cox proportional hazards regression to evaluate time to radiographic progression. Cox regression was also used to identify factors associated with psoriasis onset in the antecedent PsA group. Results: Of the 1702 patients studied, 1138 (66.86%) were classified as having classical PsA, 444 (26.09%) as having concurrent PsA, and 120 (7.05%) as having antecedent PsA. These groups differed in baseline demographic and PsA-related characteristics. Compared with patients with classical PsA, those with concurrent or antecedent PsA showed no significant differences in time-averaged disease activity or time to radiographic progression. Biologic disease-modifying antirheumatic drug (bDMARD) use was associated with a reduced risk of developing psoriasis in the group with antecedent PsA. Conclusion: The relative order of psoriasis and PsA diagnosis does not significantly affect disease activity or radiographic progression. bDMARDs may influence the onset of psoriasis in patients with antecedent PsA.

  • Atlantoaxial Subluxation in Patients With Psoriatic Arthritis

    by Virginia Carrizo-Abarza, Fadi Kharouf, Pankti Mehta, Shangyi Gao, Daniel Pereira, Richard J. Cook, Denis Poddubnyy, Dafna D. Gladman, Vinod Chandran

    Objective: We aimed to investigate the prevalence and incidence of atlantoaxial subluxation (AAS) in psoriatic arthritis (PsA), identify associated risk factors, and describe the clinical and radiographic characteristics of affected patients. Methods: We included individuals from our observational cohort of PsA, excluding those with a history of trauma or cervical spine surgery. We calculated prevalence and incidence of AAS, and we used descriptive statistics to summarize and compare baseline demographic and disease-related characteristics between patients with and without AAS. Additionally, we used Cox regression with time-varying covariates to identify factors linked to AAS development and performed multivariable generalized estimating equations (GEE) analysis to assess associations with AAS. Results: Among 1535 patients with PsA, 34 (2.21%) were identified with AAS, including 20 at baseline and 14 during follow-up, with an incidence of 1.16 per 1000 person-years. Patients with AAS had higher rates of radiographic sacroiliitis (64.71%) and greater peripheral joint damage. Elevated erythrocyte sedimentation rate (ESR) was observed in 84.85% of cases. Cox regression identified radiographic sacroiliitis (hazard ratio [HR] 6.61, 95% CI 1.64-26.67) as the strongest predictor of AAS, whereas male sex was associated with a lower hazard (HR 0.25, 95% CI 0.07-0.89). In GEE analysis, radiographic sacroiliitis (odds ratio [OR] 3.64, 95% CI 1.61-8.24) and higher modified Steinbrocker scores (OR 1.01, 95% CI 1.00-1.02) were associated with AAS, whereas older age (OR 0.95, 95% CI 0.92-0.98) and male sex (OR 0.40, 95% CI 0.17-0.92) were associated with lower ORs. Conclusion: AAS is an uncommon complication in PsA strongly associated with radiographic sacroiliitis and radiographic damage in peripheral joints.